ADHD

The CDC just released new data that highlight issues around adult ADHD prevalence, diagnosis, and treatment.

A new study of adult emergency department admissions found that individuals taking high doses of amphetamine—like Adderall—have a 5-fold increased risk for developing psychosis or mania.

Guidelines from the World Health Organization's Mental Health Gap Action Program support nonspecialist health workers providing evidence-based treatments in underresourced regions.

The CDC suggests that disrupted access to ADHD medications may increase risk of overdose and injury.

Do physical health conditions in childhood affect ADHD symptoms at age 17 years? Researchers investigated these associations in a large cohort study.

Onyda XR is the first and only liquid nonstimulant ADHD medication approved in the US and the only approved nonstimulant ADHD medication with nighttime dosing.

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Here are highlights from the week in Psychiatric Times.

The company has announced plans to submit the NDA in the first half of 2025.

Here are highlights from the first day of this year’s APA Annual Meeting.

This 2024 APA Annual Meeting poster covered a literature review on the relationship between stimulant use and failure to thrive in pediatric patients with ADHD.

A look at 3 different psychiatric perspectives for successfully diagnosing ADHD in previously undiagnosed adults.

What are the connections between what we eat and disorders such as anxiety and depression?

What is new in research on opioid use disorder?

Tris Pharma has formed the organization along with a licensing agreement with Braingaze for development, distribution of the technology.

“The heart of the matter.” Researchers investigated the risk of cardiovascular disease associated with long-term ADHD medication use.

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

What is new in research on child and adolescent psychiatry?

Here’s why ADHD is a diagnosis of exclusion.

What is new in research on ADHD?

The experts weighed in on a wide variety of psychiatric issues for the February 2024 issue of Psychiatric Times.

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.

From noninvasive brain stimulation for substance use disorders to updates from APSARD 2024, here are highlights from the week in Psychiatric Times.

Check out these APSARD 2024 updates from Greg Mattingly, MD, president of the American Professional Society for ADHD and Related Disorders.

This APSARD 2024 conference poster finds that individuals with ADHD have distinct motivations and patterns of substance use.

The results were shared in a poster presentation at the 2024 APSARD Annual Meeting.

APSARD tackles the first US adult ADHD treatment guidelines.

Here are highlights from some of the year’s top features in Psychiatric Times from throughout 2023.

Reviewing a year of CMEs in Psychiatric Times®